Biogen Idec ’s PLEGRIDY™(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis
Research and Markets: Global Multiple Sclerosis Drugs Market 2014-2018 Featuring Bayer, Biogen Idec , Merck Serono, Novartis & Teva Pharmaceutical
UPDATE: Biotech companies take the real ice bucket challenge
Research and Markets: Growth Factors (Blood and Tissue) Market 2014 - Global Strategic Business Report
Isis Pharmaceuticals Earns $2M from the Advancement of ISIS-SMN Rx in Children with Spinal Muscular Atrophy
All investments involve risk, including possible loss of principal. The value of investments can go down as well as up, and investors may not get back the full amount invested. The information provided in this posting is not a complete analysis of every material fact regarding any country, region, ...
Biotech companies' returns have diverged from the broader market in recent weeks amid concerns over greater regulation and price discounting.
A handful of health-care names are selling at premiums now, but buying opportunities are surfacing, as well.